title: Subcutaneous bortezomib for multiple myeloma treatment: patients' benefits.
abstract: The use of novel agents such as thalidomide, lenalidomide, and bortezomib has considerably improved the outcome of multiple myeloma patients. Besides greater biological activity, these drugs unfortunately have also been associated with greater toxicity. To evaluate the positive effect on the quality of life of patients, driven by both the tolerability and antimyeloma activity of bortezomib, we analyzed data that have been published concerning different strategies used to improve its tolerability as once weekly and/or subcutaneous administration.
authors.affiliation: Department of Cellular Biotechnology and Hematology, Sapienza University of Rome, Italy.
authors.forename: Maria Teresa
authors.initials: MT
authors.lastname: Petrucci
authors.affiliation: Department of Cellular Biotechnology and Hematology, Sapienza University of Rome, Italy.
authors.forename: Paola
authors.initials: P
authors.lastname: Finsinger
authors.affiliation: Department of Cellular Biotechnology and Hematology, Sapienza University of Rome, Italy.
authors.forename: Marta
authors.initials: M
authors.lastname: Chisini
authors.affiliation: Department of Cellular Biotechnology and Hematology, Sapienza University of Rome, Italy.
authors.forename: Fabiana
authors.initials: F
authors.lastname: Gentilini
keywords: intravenous bortezomib; patient preference; quality of life